Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study
- 31 December 2008
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 9 (12), 1135-1142
- https://doi.org/10.1016/s1470-2045(08)70261-4
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small cell lung cancerLung Cancer, 2006
- Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancerLung Cancer, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)Clinical Cancer Research, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- O-272 A randomized phase II study of carboplatin/gemcitabine (CG) versus vinorelbine/gemcitabine (VG) in patients (pts) with advanced Non-Small Cell Lung Cancer (NSCLC); West Japan Thoracic Oncology Group (WJTOG) 0104Lung Cancer, 2003
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958